Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Dec;227(3):129-41.
doi: 10.1530/JOE-15-0280. Epub 2015 Oct 20.

Hypothalamic leptin gene therapy reduces body weight without accelerating age-related bone loss

Russell T Turner  1 , Michael Dube  2 , Adam J Branscum  2 , Carmen P Wong  2 , Dawn A Olson  2 , Xiaoying Zhong  2 , Mercedes F Kweh  2 , Iske V Larkin  2 , Thomas J Wronski  2 , Clifford J Rosen  2 , Satya P Kalra  2 , Urszula T Iwaniec  3
Affiliations

Hypothalamic leptin gene therapy reduces body weight without accelerating age-related bone loss

Russell T Turner et al. J Endocrinol. 2015 Dec.

Abstract

Excessive weight gain in adults is associated with a variety of negative health outcomes. Unfortunately, dieting, exercise, and pharmacological interventions have had limited long-term success in weight control and can result in detrimental side effects, including accelerating age-related cancellous bone loss. We investigated the efficacy of using hypothalamic leptin gene therapy as an alternative method for reducing weight in skeletally-mature (9 months old) female rats and determined the impact of leptin-induced weight loss on bone mass, density, and microarchitecture, and serum biomarkers of bone turnover (CTx and osteocalcin). Rats were implanted with cannulae in the 3rd ventricle of the hypothalamus and injected with either recombinant adeno-associated virus encoding the gene for rat leptin (rAAV-Leptin, n=7) or a control vector encoding green fluorescent protein (rAAV-GFP, n=10) and sacrificed 18 weeks later. A baseline control group (n=7) was sacrificed at vector administration. rAAV-Leptin-treated rats lost weight (-4±2%) while rAAV-GFP-treated rats gained weight (14±2%) during the study. At study termination, rAAV-Leptin-treated rats weighed 17% less than rAAV-GFP-treated rats and had lower abdominal white adipose tissue weight (-80%), serum leptin (-77%), and serum IGF1 (-34%). Cancellous bone volume fraction in distal femur metaphysis and epiphysis, and in lumbar vertebra tended to be lower (P<0.1) in rAAV-GFP-treated rats (13.5 months old) compared to baseline control rats (9 months old). Significant differences in cancellous bone or biomarkers of bone turnover were not detected between rAAV-Leptin and rAAV-GFP rats. In summary, rAAV-Leptin-treated rats maintained a lower body weight compared to baseline and rAAV-GFP-treated rats with minimal effects on bone mass, density, microarchitecture, or biochemical markers of bone turnover.

Keywords: dual energy absorptiometry; microcomputed tomography; rAAV-Leptin; white adipose tissue.

PubMed Disclaimer

Conflict of interest statement

Declaration of interest: The authors have nothing to declare.

Figures

Figure 1
Figure 1
Effects of increased hypothalamic leptin via rAAV-Leptin therapy on body weight over time (A), body weight change (B), abdominal white adipose tissue (WAT) weight (C), food intake over time (D), and cumulative food intake (E). Values are mean ± SE, n=7–10/group. aDifferent from rAAV-GFP, p ≤ 0.05. a*Different from rAAV-GFP, p < 0.1.
Figure 2
Figure 2
Effects of increased hypothalamic leptin via rAAV-Leptin therapy on leptin (A) and NPY (B) mRNA expression in hypothalamus, and leptin (C) and IGF1 (D) mRNA expression in abdominal white adipose tissue. Values are mean ± SE, n=7–10/group. aDifferent from rAAV-GFP, p ≤ 0.05.
Figure 3
Figure 3
Effects of increased hypothalamic leptin via rAAV-Leptin therapy on serum leptin (A), IGF1 (B), growth hormone (C), glucose (D), adiponectin (E), CTx (F), and osteocalcin (G). Values are mean ± SE, n=7–10/group. aDifferent from rAAV-GFP, p ≤ 0.05.
Figure 4
Figure 4
Effects of increased hypothalamic leptin via rAAV-Leptin therapy on femur area (A), bone mineral content (B), and bone mineral density (C). Values are mean ± SE, n=7–10/group. a*Different from Baseline, p < 0.1. b*Different from rAAV-GFP, p < 0.1.
See this image and copyright information in PMC

References

    1. Arounleut P, Bowser M, Upadhyay S, Shi XM, Fulzele S, Johnson MH, Stranahan AM, Hill WD, Isales CM, Hamrick MW. Absence of functional leptin receptor isoforms in the POUND (Lepr(db/lb)) mouse is associated with muscle atrophy and altered myoblast proliferation and differentiation. PLoS One. 2013;8:e72330. - PMC - PubMed
    1. Bagnasco M, Dube MG, Kalra PS, Kalra SP. Evidence for the existence of distinct central appetite, energy expenditure, and ghrelin stimulation pathways as revealed by hypothalamic site-specific leptin gene therapy. Endocrinology. 2002;143:4409–4421. - PubMed
    1. Banks WA, DiPalma CR, Farrell CL. Impaired transport of leptin across the blood-brain barrier in obesity. Peptides. 1999;20:1341–1345. - PubMed
    1. Banks WA, Kastin AJ, Huang W, Jaspan JB, Maness LM. Leptin enters the brain by a saturable system independent of insulin. Peptides. 1996;17:305–311. - PubMed
    1. Banks WA, Lebel CR. Strategies for the delivery of leptin to the CNS. J Drug Target. 2002;10:297–308. - PubMed

Publication types